Chronic activation of the aryl hydrocarbon receptor in muscle exacerbates ischemic pathology in chronic kidney disease.
Nicholas BalestrieriVictoria PalzkillCaroline PassJianna TanZachary R SalyersChatick MoparthyAnia MurilloKyoungrae KimTrace ThomeQingping YangKerri A O'MalleyScott A BerceliFeng YueSalvatore T ScaliLeonardo F FerreiraTerence E RyanPublished in: bioRxiv : the preprint server for biology (2023)
Chronic kidney disease (CKD) accelerates the development of atherosclerosis, decreases muscle function, and increases the risk of amputation or death in patients with peripheral artery disease (PAD). However, the cellular and physiological mechanisms underlying this pathobiology are ill-defined. Recent work has indicated that tryptophan-derived uremic toxins, many of which are ligands for the aryl hydrocarbon receptor (AHR), are associated with adverse limb outcomes in PAD. We hypothesized that chronic AHR activation, driven by the accumulation of tryptophan-derived uremic metabolites, may mediate the myopathic condition in the presence of CKD and PAD. Both PAD patients with CKD and mice with CKD subjected to femoral artery ligation (FAL) displayed significantly higher mRNA expression of classical AHR-dependent genes ( Cyp1a1 , Cyp1b1 , and Aldh3a1 ) when compared to either muscle from the PAD condition with normal renal function ( P <0.05 for all three genes) or non-ischemic controls. Skeletal-muscle-specific AHR deletion in mice (AHR mKO ) significantly improved limb muscle perfusion recovery and arteriogenesis, preserved vasculogenic paracrine signaling from myofibers, increased muscle mass and contractile function, as well as enhanced mitochondrial oxidative phosphorylation and respiratory capacity in an experimental model of PAD/CKD. Moreover, viral-mediated skeletal muscle-specific expression of a constitutively active AHR in mice with normal kidney function exacerbated the ischemic myopathy evidenced by smaller muscle masses, reduced contractile function, histopathology, altered vasculogenic signaling, and lower mitochondrial respiratory function. These findings establish chronic AHR activation in muscle as a pivotal regulator of the ischemic limb pathology in PAD. Further, the totality of the results provide support for testing of clinical interventions that diminish AHR signaling in these conditions.
Keyphrases
- skeletal muscle
- chronic kidney disease
- end stage renal disease
- insulin resistance
- high fat diet induced
- peripheral artery disease
- poor prognosis
- ischemia reperfusion injury
- adipose tissue
- physical activity
- sars cov
- gene expression
- type diabetes
- ms ms
- cardiovascular disease
- emergency department
- blood brain barrier
- binding protein
- weight loss
- genome wide
- transcription factor
- late onset
- computed tomography